Naproxen
(2S)-2-(6-Methoxynaphthalen-2-yl)propanoic acid
Drag to rotate. Structure from PubChem CID 156391.
Background
Listing
- Schedules
- Schedule 1 to 3, conditions apply
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
2 registered products listed
Counted through the register's ingredient index, which does not reach every record.
| Name | Brands | Dosages | Applicants | Registrations | Schedule |
|---|---|---|---|---|---|
| Naproxen | Pranoxen, Napgesic, Nafasol ec, +24 more | 220 mg, 250 mg, 275 mg, 500 mg, +2 more | 15 applicants | 37 registrations | S1 to S3conditions apply |
| Esomeprazole, naproxen | Rarzulite, Vimovo | 500/20, 500 mg/20 mg | Adcock ingram limited | 2 registrations | S1 to S4conditions apply |
Regulatory status
Where S1 to S3 sits on the scale
Depends on which listing applies
At the least restrictive, Schedule 1: sold by a pharmacist, no doctor's prescription needed. At the most restrictive, Schedule 3: needs a doctor's prescription, dispensed by a pharmacist. The listings below say which applies to which form, strength or pack size.
Schedule S1 to S3, as the Consolidated Schedules list it.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Naproxen
S3: Naproxen
- except when contained in preparations intended for application to the skin; (S1, S2)
- except when contained in oral medicinal preparations, intended for human use only containing naproxen as the only active therapeutic substance intended for patients over 16 years of age, for the treatment of mild to moderate pain or fever of inflammatory origin at a maximum dose of 600 milligrams naproxen base (660 milligrams naproxen sodium) in a 24 hour period for a maximum treatment period of 5 days and supplied in a solid dose form as divided doses contained in packs not exceeding the stated maximum treatment peroid. (S1, S2)
- except when intended for the treatment of acute gout attacks, for a maximum treatment period of 5 days in patients over 16 years of age. (S1, S2)
Consolidated Schedules 06 July 2026, lines 3978 to 3994
S2: Naproxen
- when intended for the treatment of acute gout attacks, for a maximum treatment period of 5 days in patients over 16 years of age; (S3)
- except when contained in preparations intended for application to the skin;(S1) and
- except when contained in oral medicinal preparations, intended for human use only containing naproxen as the only active therapeutic substance intended for patients over 16 years of age, for the treatment of mild to moderate pain or fever of inflammatory origin at a maximum dose of 600 milligrams naproxen base (660 milligrams naproxen sodium) in a 24 hour period for a maximum treatment period of 5 days and supplied in a solid dose form as divided doses contained in packs not exceeding the stated maximum treatment period; (S1, S3)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 2368 to 2386
S1: Naproxen
- when contained in preparations intended for application to the skin; (S2, S3)
- when contained in oral medicinal preparations, intended for human use only containing naproxen as the only active therapeutic substance intended for patients over 16 years of age, for the treatment of mild to moderate pain or fever of inflammatory origin at a maximum dose of 600 milligrams naproxen base (660 milligrams naproxen sodium) in a 24 hour period for a maximum treatment period of 5 days and supplied in a solid dose form as divided doses contained in packs not exceeding the stated maximum treatment period; (S2, S3)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 866 to 877
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.